FrancophonIA/ELRC3.0 huggingface dataset:
English: It is not intended to provide practical advice on how to use Atosiban SUN.
Estonian: Hindamisaruandes ei anta ravimi Atosiban SUN kasutamise praktilisi nõuandeid.
English: How has Atosiban SUN been studied?
Estonian: Kuidas ravimit Atosiban SUN uuriti?
English: What are the benefits and risks of Atosiban SUN?
Estonian: Milles seisneb ravimi Atosiban SUN kasulikkus ja mis riskid ravimiga kaasnevad?
English: How is Atosiban SUN used?
Estonian: Kuidas ravimit Atosiban SUN kasutatakse?
English: Atosiban SUN is available as a solution for injection and as a concentrate that is made up into a solution for infusion
Estonian: Ravimit Atosiban SUN turustatakse süstelahuse ja infusioonilahuse (veeni tilgutatava lahuse) valmistamise
English: The European Commission granted a marketing authorisation valid throughout the EU for Stronghold Plus on 9 February 2017.
Estonian: Euroopa Komisjon andis Stronghold Plusi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 9. veebruaril 2017.
English: The full EPAR for Stronghold Plus can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Stronghold Plusi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: On the day of treatment, treated cats must not be allowed to sleep in the same bed as their owner, especially children.
Estonian: Ravipäeval ei tohi ravitud kassidel lubada magada samas voodis koos omanikuga, eriti koos lastega.
English: Children must not be allowed to play with treated cats for 4 hours after treatment.
Estonian: Lastel ei tohi lasta ravitud kassidega mängida 4 tunni jooksul pärast ravimi manustamist.
English: This summary was last updated in December 2016.
Estonian: Kokkuvõtte viimane uuendus: 12-2016.
English: Stronghold Plus selamectin / sarolaner
Estonian: Stronghold Plus selamektiin/sarolaner
English: Treated animals must not be touched until the application area is dry.
Estonian: Ravitavaid loomi ei tohi puudutada enne, kui manustamiskoht on kuiv.
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Stronghold Plus's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Veterinaarravimite komitee järeldas, et Stronghold Plusi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: Selamectin and sarolaner are antiparasitic medicines.
Estonian: Selamektiin ja sarolaner on antiparasiitikumid.
English: What is Stronghold Plus and what is it used for?
Estonian: Mis on Stronghold Plus ja milleks seda kasutatakse?
English: The strength and number of pipettes used depends on the weight of the cat being treated.
Estonian: Kasutatavate pipettide tugevus ja arv sõltub ravitava kassi kaalust.
English: In order to be exposed to selamectin and sarolaner, fleas and ticks must commence feeding on the cat's blood.
Estonian: Selamektiini ja sarolaneriga kokkupuutumiseks peavad kirbud ja puugid imema kassi verd.
English: Stronghold Plus kills fleas and some ticks within 24 hours and it continues to work for 5 weeks against fleas and 4 to 5 weeks against ticks (depending on the type).
Estonian: Stronghold Plus tapab kirbud ja teatud liiki puugid 24 tunni jooksul; kirbuvastane toime kestab 5 nädalat ja puugivastane toime 4-5 nädalat, olenevalt liigist.
English: People with sensitive skin or who are hypersensitive (allergic) to selamectin or sarolaner should handle Stronghold Plus with caution.
Estonian: Tundliku nahaga või selamektiini või sarolaneri suhtes allergilised (ülitundlikud) inimesed peavad Stronghold Plusi käsitsema ettevaatlikult.
English: Stronghold Plus contains two active substances, selamectin and sarolaner.
Estonian: Stronghold Plus sisaldab kahte toimeainet: selamektiini ja sarolaneri.
English: Other information about Stronghold Plus
Estonian: Muu teave Stronghold Plusi kohta
English: It is not intended to provide practical advice on how to use Stronghold Plus.
Estonian: Hindamisaruandes ei anta Stronghold Plusi kasutamise praktilisi nõuandeid.
English: Stronghold Plus must not be used in cats suffering from other diseases or in cats that are weak and underweight (for their age).
Estonian: Stronghold Plusi ei tohi kasutada kassidel, kel on muid haigusi või kes on vanuse tõttu nõrgad ja alakaalulised.
English: Why is Stronghold Plus approved?
Estonian: Miks Stronghold Plus heaks kiideti?
English: Hands should be washed after use and any product in contact with the skin should be washed off immediately with soap and water.
Estonian: Pärast kasutamist tuleb pesta käsi ning nahale sattunud ravim tuleb otsekohe pesta ära vee ja seebiga.
English: Stronghold Plus is a medicine used to treat mixed infestations with both ticks and other parasites that may be found on the skin or fur of cats, such as fleas, ear mites and lice and/or worms that live inside the body.
Estonian: Stronghold Plus on ravim, mida kasutatakse selliste seganakkuste raviks, mille põhjustajaks on puugid ja muud kasside nahal või karvkattes leiduvad parasiidid, nagu kirbud, kuulmelestad ja täid, ja/või organismis elutsevad ussid.
English: The effectiveness of Stronghold Plus was investigated in a field study in cats naturally infested with fleas.
Estonian: Stronghold Plusi efektiivsust uuriti väliuuringus looduslikult kirpudega nakatunud kassidel.
English: Stronghold Plus must only be used when there is a need to treat ticks and one or more of the above parasites.
Estonian: Stronghold Plus on näidustatud kasutamiseks puukide ja ühe või mitme teise eelnimetatud parasiidi vastu.
English: Use of the medicine may result in mild and short-lived itching at the application site.
Estonian: Ravimi kasutamisel võib esineda kerget mööduvat sügelust manustamiskohal.
English: Stronghold Plus is highly flammable and should be kept away from heat, sparks, any open flame or other sources of ignition.
Estonian: Stronghold Plus on väga tuleohtlik ning seda tuleb kaitsta soojuse, sädemete, lahtise leegi ja muude süttimisallikate eest.
English: Stronghold Plus was as effective as the other medicine and reduced tick counts by more than 90%.
Estonian: Stronghold Plus osutus sama efektiivseks kui teine ravim ja vähendas puukide arvu enam kui 90% võrra.
English: Selamectin activates special proteins called ‘chloride channels' on the surface of nerve and muscle cells of the parasite, allowing charged chloride particles to enter nerve cells and disrupting their normal electrical activity.
Estonian: Selamektiin aktiveerib parasiidi närvi- ja lihaserakkude pinnal olevad teatud valgud, nn kloriidikanalid, mille kaudu sisenevad kloriidiioonid närvirakkudesse ja häirivad nende normaalset elektrilist talitlust.
English: The most common side effects with Stronghold Plus (which may affect up to 1 in 100 cats) are mild to moderate alopecia (hair loss) at the application site, erythema (reddening of the skin) and drooling saliva.
Estonian: Stronghold Plusi kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 kassil 100st) on kerge kuni mõõdukas alopeetsia (karvakadu) manustamiskohal, erüteem (nahapunetus) ja suurenenud süljeeritus.
English: What are the risks associated with Stronghold Plus?
Estonian: Mis riskid Stronghold Plusiga kaasnevad?
English: Sarolaner blocks the normal movement of charged chloride particles in and out of nerve cells, especially those associated with gamma-aminobutyric acid (GABA) and glutamate, two substances that convey messages between nerves (neurotransmitters).
Estonian: Sarolaner takistab eelkõige neurotransmitterite gamma-aminovõihappe (GABA) ja glutamaadiga seondunud kloriidiioonide normaalset liikumist närvirakkudesse ja neist välja.
English: This is a summary of the European public assessment report (EPAR) for Stronghold Plus.
Estonian: See on ravimi Stronghold Plus Euroopa avaliku hindamisaruande kokkuvõte.
English: Stronghold Plus is harmful after swallowing.
Estonian: Stronghold Plusi allaneelamine on kahjulik.
English: Safety information has been included in the summary of product characteristics and the package leaflet for Stronghold Plus, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers.
Estonian: Ravimi omaduste kokkuvõttesse ja pakendi infolehele lisati Stronghold Plusi ohutusteave, kus on ka tervishoiuspetsialistide ja loomaomanike või -pidajate võetavad meetmed.
English: Stronghold Plus was as effective as the other medicine and reduced flea counts by more than 95%.
Estonian: Stronghold Plus osutus sama efektiivseks kui teine ravim ja vähendas kirpude arvu enam kui 95% võrra.
English: For practical information about using Stronghold Plus, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Estonian: Kui loomaomanikud või -pidajad vajavad Stronghold Plusi kasutamise praktilisi nõuandeid, peavad nad lugema pakendi infolehte või pöörduma oma veterinaararsti või apteekri poole.
English: How is Stronghold Plus used?
Estonian: Kuidas Stronghold Plusi kasutatakse?
English: It is recommended to treat cats in the evening.
Estonian: Ravimit on soovitatav manustada õhtul.
English: Sarolaner is effective against ticks and fleas.
Estonian: Sarolaneril on puugi- ja kirbuvastane toime.
English: Stronghold Plus is available as a spot-on solution in three different strengths and can only be obtained with a prescription.
Estonian: Stronghold Plusi turustatakse kolme erineva tugevusega täpilahusena ja see on retseptiravim.
English: In case of skin or eye contact the affected area should be rinsed immediately with water.
Estonian: Ravimi juhuslikul sattumisel nahale või silma tuleb seda kohta otsekohe veega pesta.
English: A laboratory study with cats artificially infected with heartworm showed Stronghold Plus to be effective for the prevention of heartworm disease.
Estonian: Laboriuuringus, milles kassid nakatati laboris südameussidega, osutus Stronghold Plus efektiivseks südameusstõve ennetamisel.
English: Two laboratory studies with cats artificially infested with ear mites showed Stronghold Plus to reduce ear mites by more than 90% 30 days after a single treatment.
Estonian: Kahes laboriuuringus, milles kassid nakatati laboris kuulmelestadega, vähendas Stronghold Plus ühekordsest manustamisest 30 päeva möödudes kuulmelestade arvu enam kui 90% võrra.
English: Cats were treated with Stronghold Plus monthly for 3 months or another antiparasitic medicine, containing imidacloprid and moxidectin.
Estonian: Kassidele manustati kolme kuu jooksul (kord kuus) Stronghold Plusi või teist antiparasiitikumi, mis sisaldas toimeainetena imidaklopriidi ja moksidektiini.
English: Selamectin is effective against fleas, ear mites, biting lice, heartworms, roundworms and hookworms.
Estonian: Selamektiinil on kirpude, kuulmelestade, täide, südameusside, ümarusside ja nugiliste vastane toime.
English: Cats were treated with Stronghold Plus monthly for 3 months or another medicine, containing fipronil.
Estonian: Kassidele manustati kolme kuu jooksul (kord kuus) Stronghold Plusi või teist ravimit, mis sisaldas toimeainena fiproniili.
English: • to prevent heartworm disease
Estonian: • südameusstõve ennetamiseks.
English: The contents of the pipette are squeezed onto the skin after parting the fur at the base of the cat's neck in front of the shoulder blades.
Estonian: Looma kaela tagaosas abaluude ees surutakse karv lahku ja pipeti sisu tühjendatakse nahale.
English: What benefits of Stronghold Plus have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Stronghold Plusi kasulikkus?
English: Two laboratory studies were conducted in cats with intestinal worms which showed Stronghold Plus to have more than 94% efficacy.
Estonian: Kahes sooleparasiitidega kassidel tehtud laboriuuringus oli Stronghold Plusi efektiivsus enam kui 94%.
English: It can also be used as part of a treatment for flea allergy dermatitis (an allergic reaction to flea bites)
Estonian: (allergiline reaktsioon kirbuhammustustele) ravi osana;
English: • to treat tick infestations
Estonian: • täinakkuse raviks;
English: How does Stronghold Plus work?
Estonian: Kuidas Stronghold Plus toimib?
English: • to treat adult roundworms and adult hookworms in the gut
Estonian: • täiskasvanud ümarusside ja soolenugiliste vastaseks raviks;
English: A laboratory study with cats infested with biting lice showed selamectin to eliminate biting lice for 42 days after treatment compared to placebo treated cats.
Estonian: Platseebokontrolliga laboriuuringus, milles kassid nakatati laboris täidega, hävitas selamektiin täid 42 päevaks alates manustamisest.
English: • to treat ear mites
Estonian: • kuulmelestade raviks;
English: • to treat and prevent flea infestations.
Estonian: • kirbunakkuse raviks ja ennetamiseks; ravimit võib kasutada ka kirbuallergiast tingitud dermatiidi
English: The dose in children depends on their age.
Estonian: Laste annus sõltub nende vanusest.
English: Adults and adolescents can use any form of the medicine.
Estonian: Täiskasvanud ja noorukid võivad kasutada seda ravimit mis tahes vormis.
English: The full EPAR for Azomyr can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Azomyri kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Azomyr on 15 January 2001.
Estonian: Euroopa Komisjon andis Azomyri müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 15. jaanuaril
English: This is a summary of the European public assessment report (EPAR) for Azomyr.
Estonian: See on Azomyri Euroopa avaliku hindamisaruande kokkuvõte.
English: The Committee recommended that Azomyr be given marketing authorisation.
Estonian: Komitee soovitas anda Azomyri müügiloa.
English: Other information about Azomyr
Estonian: Muu teave Azomyri kohta
English: When the receptors are blocked, histamine cannot have its effect, and this leads to a decrease in the symptoms of allergy.
Estonian: Kui retseptorid on blokeeritud, ei saa histamiin toimet avaldada ning sellest tulenevalt allergiasümptomid vähenevad.
English: Azomyr has been studied in a total of eight studies involving about 4,800 adult and adolescent patients with allergic rhinitis (including four studies in seasonal allergic rhinitis, and two studies in patients who also had asthma).
Estonian: Azomyri uuriti kokku kaheksas uuringus, milles osales ligikaudu 4800 täiskasvanu- ja noorukieas patsienti, kellel oli allergiline riniit (sh neljas uuringus uuriti hooajalist allergilist riniiti ja kahes uuringus uuriti patsiente, kellel oli lisaks astma).
English: Additional studies were presented to show that the syrup, oral solution and orodispersible tablets are treated by the body in the same way as the tablets, and to show that they can be used safely in children.
Estonian: Esitati lisauuringud, mis tõendasid, et siirupi, suukaudse lahuse ja suus dispergeeruvate tablettidena manustatud ravimile reageerib organism samamoodi kui tablettidena manustatud ravimile, samuti tõendati nende ravimvormide kasutamise ohutust lastel.
English: Azomyr has also been studied in 416 patients with urticaria.
Estonian: Azomyri uuriti ka 416 nõgestõvega patsiendil.
English: For more information about treatment with Azomyr, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Azomyriga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: In children less than two years of age, the most common side effects are diarrhoea (3.7%), fever (2.3%) and insomnia (difficulty sleeping; 2.3%).
Estonian: Alla kaheaastastel lastel on kõige sagedamad kõrvalnähud kõhulahtisus (3,7%), palavik (2,3%) ja unetus (2,3%).
English: Azomyr is a medicine containing the active substance desloratadine.
Estonian: Azomyr on ravim, mis sisaldab toimeainena desloratadiini.
English: It works by blocking the receptors to which histamine, a substance in the body that causes allergic symptoms, normally attaches itself.
Estonian: See blokeerib retseptoreid, mille külge histamiinallergilisi sümptomeid põhjustav aine kehas - tavaliselt kinnitub.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Azomyr.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: What is Azomyr?
Estonian: Mis on Azomyr?
English: In all studies, the effectiveness of Azomyr was compared with that of placebo (a dummy treatment).
Estonian: Kõigis uuringuis võrreldi Azomyri platseeboga (näiva ravimiga).
English: The active substance in Azomyr, desloratadine, is an antihistamine.
Estonian: Azomyri toimeaine desloratadiin on antihistamiin.
English: Azomyr must not be used in people who are hypersensitive (allergic) to desloratadine, loratadine or any of the other ingredients.
Estonian: Azomyri ei tohi kasutada patsiendid, kes on desloratadiini, loratadiini või ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: The Committee for Medicinal Products for Human Use (CHMP) decided that Azomyr's benefits are greater than its risks for the relief of symptoms associated with allergic rhinitis or urticaria.
Estonian: Inimravimite komitee otsustas, et Azomyri kasulikkus allergilise riniidi või nõgestõvega kaasnevate sümptomite leevendamisel on suurem kui kaasnevad riskid.
English: What is the risk associated with Azomyr?
Estonian: Mis riskid Azomyriga kaasnevad?
English: For the full list of all side effects reported with Azomyr, see the Package Leaflet.
Estonian: Azomyri kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: The effectiveness was measured by looking at the change in the symptoms (itching, number and size of hives, interference with sleep and daytime function) before and after six weeks of treatment.
Estonian: Ravimi efektiivsust hinnati sümptomite (sügelus, nõgestõve kuplade arv ja suurus, une- ja ärkvelolekuaeg) muutuste kaudu enne ja pärast kuuenädalast ravi.
English: Why has Azomyr been approved?
Estonian: Miks Azomyr heaks kiideti?
English: The effectiveness of Azomyr was measured by looking at the change in the symptoms (nasal discharge, itching, sneezing and congestion) before and after two or four weeks of treatment.
Estonian: Azomyri efektiivsust hinnati sümptomite (ninaeritised, sügelus, aevastamine ja ninakinnisus) muutuste kaudu enne ja pärast kahe- või neljanädalast ravi.
English: Azomyr is used to relieve the symptoms of allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) or urticaria (a skin condition caused by an allergy, with symptoms including itching and hives).
Estonian: Azomyri kasutatakse allergilise riniidi (allergiast, nt heinapalavikust või tolmulestade allergiast põhjustatud ninaõõnepõletik) või nõgestõve (allergiast põhjustatud nahaseisund, mille sümptomite hulka kuuluvad sügelus ja nahakublad) sümptomite leevendamiseks.
English: In allergic rhinitis, looking at the results of all studies taken together, two weeks of treatment with 5 mg Azomyr led to an average decrease in symptom score of 25 to 32%, compared with a decrease of 12 to 26% in the patients receiving placebo.
Estonian: Kõigis allergilise riniidi uuringuis vähendas kahenädalane ravi 5 mg Azomyriga sümptomite hindamise keskmist punktisummat tulemuselt 25% tulemusele 32%, platseeborühmas aga tulemuselt 12% tulemusele 26%.
English: In the two studies in urticaria, the decrease in symptom score after six weeks of treatment with Azomyr was 58 and 67%, compared with 40 and 33% in placebo-treated patients.
Estonian: Nõgestõve kahes uuringus vähenes Azomyri kuuenädalase ravi järel sümptomite punktisumma tulemuselt 58% tulemusele 67%, platseeborühmas aga tulemuselt 40% tulemusele
English: How does Azomyr work?
Estonian: Kuidas Azomyr toimib?
English: How has Azomyr been studied?
Estonian: Kuidas Azomyri uuriti?
English: How is Azomyr used?
Estonian: Kuidas Azomyri kasutatakse?
English: What benefit has Azomyr shown during the studies?
Estonian: Milles seisneb uuringute põhjal Azomyri kasulikkus?
English: What is Azomyr used for?
Estonian: Milleks Azomyri kasutatakse?
English: Annex I List of the names, pharmaceutical form, strength of the medicinal products, route of administration, marketing authorisation holders in the Member States
Estonian: Lisa I Ravimi nimetuste, ravimvormide, tugevuste, manustamisviiside, müügiloa hoidjate loetelu liikmesriikides
English: FENOFIBRATO PENSA 160 mg comprimidos recubiertos con película EFG 160 mg Film-coated tablet Oral use
Estonian: FENOFIBRATO PENSA 160 mg comprimidos recubiertos con película EFG
English: FENOFIBRATO RANBAXY 160 mg comprimidos recubiertos con película EFG 160 mg Film-coated tablet Oral use
Estonian: FENOFIBRATO RANBAXY 160 mg comprimidos recubiertos con película EFG
English: The European Medicines Agency has deferred the obligation to submit the final results of this study.
Estonian: Euroopa Ravimiamet on edasi lükanud selle uuringu lõplike tulemuste esitamise kohustuse.
English: The median time to surgery was 261 days.
Estonian: Mediaanne aeg kirurgiani oli 261 päeva.
English: 1 CI = Exact Confidence Interval
Estonian: 1 CI = täpne usaldusvahemik
English: Date of latest renewal: 4 April 2016
Estonian: Müügiloa viimase uuendamise kuupäev: 4. aprill 2016
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 13 July 2011
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE/MÜÜGILOA UUENDAMISE KUUPÄEV Müügiloa esmase väljastamise kuupäev: 13. juuli 2011
English: It is important to tell your doctor if you are pregnant, think you may be pregnant, or plan to get pregnant.
Estonian: On tähtis öelda oma arstile, kui te olete rase, arvate, et võite olla rase või plaanite rasestuda.
English: Efficacy results from study 4 are presented in figure 2 and table 3.
Estonian: Uuringu 4 tulemusnäitajad on esitatud joonisel 2 ja tabelis 3.
English: Clinical characteristics of these cases were similar between treatment groups.
Estonian: Nende juhtude kliinilised omadused olid ravirühmade vahel sarnased.
English: It is especially important that you tell your doctor if you are being treated with
Estonian: Eriti oluline on teavitada oma arsti, kui teid ravitakse
English: In rare cases allergic reactions may be severe.
Estonian: Harva on allergiliste reaktsioonide juhud rasked.
English: 1 See section Description of selected adverse reactions 2 See section Other special populations 3 See section 4.4
Estonian: 1 Vt alalõik „Valitud kõrvaltoimete kirjeldus“ 2 Vt alalõik „Teised eripopulatsioonid“ 3 Vt lõik 4.4
English: Following subcutaneous administration, bioavailability was 62%.
Estonian: Pärast subkutaanset manustamist oli biosaadavus 62%.
English: These pain improvements were maintained at all subsequent evaluations.
Estonian: Valu vähenemine oli püsiv kõikides järgnevates hinnangutes.
English: The median duration of response was not estimable (four patients experienced disease progressions following an objective response).
Estonian: Ravivastuse mediaanne kestus ei olnud hinnatav (neljal patsiendil haigus progresseerus pärast objektiivset ravivastust).
English: Other medicines and XGEVA
Estonian: Muud ravimid ja XGEVA
English: Based on these limited data, the adverse event profile appeared to be similar to adults.
Estonian: Nende piiratud andmete alusel sarnanes kõrvaltoimete profiil täiskasvanute omaga.
English: Most subjects were receiving or had received chemotherapy.
Estonian: Enamik isikuid sai või oli saanud keemiaravi.
English: This study did not control for prognostic factors and anti-neoplastic treatments.
Estonian: Antud uuringus ei arvestatud prognostiliste faktorite ja kasvajavastase raviga.